ZTS
Zoetis Inc.
Price Chart
Latest Quote
$79.44
| Previous Close | $79.52 |
| Open | $79.54 |
| Day High | $81.19 |
| Day Low | $79.44 |
| Volume | 5,289,447 |
Stock Information
| Quarterly Dividend / Yield | $2.12 / 2.67% |
| Shares Outstanding | 419.23M |
| Quarterly Dividend Yield | 2.67% |
| Quarterly Dividend | $2.12 |
| Total Debt | $9.25B |
| Cash Equivalents | $1.94B |
| Revenue | $9.53B |
| Net Income | $2.67B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $33.30B |
| P/E Ratio | 13.02 |
| EPS (TTM) | $6.10 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $40.65B |
| Sales | $9.53B |
| Income | $2.67B |
| Book/sh | $7.84 |
| Cash/sh | $4.63 |
| Employees | 14K |
Financial Ratios
| Quick Ratio | 1.68 |
| Current Ratio | 3.15 |
| Debt/Eq | 286.24 |
| EPS Growth TTM | -0.20% |
Returns & Margins
| ROA | 15.53% |
| ROE | 67.75% |
| Gross Margin | 71.84% |
| Operating Margin | 36.56% |
| Profit Margin | 28.04% |
Ownership
| Insider Ownership | 0.15% |
| Institutional Ownership | 102.90% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.70 |
| PEG | 1.83 |
| P/S | 3.49 |
| P/B | 10.13 |
Analyst Data
| Recommendation | buy |
| Target Price | $124.59 |
Technical Indicators
| SMA20 | $78.22 |
| SMA50 | $100.89 |
| SMA200 | $123.22 |
| RSI | 67.13 |
| ATR | 2.6321 |
| Shares Float | 418.38M |
| Short Float | 3.60% |
| Short Ratio | 1.79 |
| Volatility | 0.74 |
| Rel Volume | 0.57 |
Performance History
| Week | +2.25% |
| Month | -28.57% |
| Quarter | -34.30% |
| 6 Months | -34.63% |
| YTD | -36.37% |
| Year | -52.15% |
| 3 Years | -49.47% |
| 5 Years | -52.71% |
| 10 Years | +78.27% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $79.44 | 5,289,447 |
| 2026-06-04 | $79.52 | 7,355,200 |
| 2026-06-03 | $77.59 | 8,105,400 |
| 2026-06-02 | $76.39 | 7,651,500 |
| 2026-06-01 | $77.56 | 5,046,700 |
| 2026-05-29 | $77.69 | 9,295,100 |
| 2026-05-28 | $78.27 | 7,686,200 |
| 2026-05-27 | $79.48 | 7,874,000 |
| 2026-05-26 | $80.23 | 5,696,600 |
| 2026-05-22 | $81.32 | 6,327,100 |
| 2026-05-21 | $80.07 | 8,564,800 |
| 2026-05-20 | $79.71 | 7,404,700 |
| 2026-05-19 | $78.92 | 7,295,300 |
| 2026-05-18 | $77.72 | 8,848,300 |
| 2026-05-15 | $74.22 | 8,952,000 |
| 2026-05-14 | $75.48 | 8,714,800 |
| 2026-05-13 | $74.34 | 13,085,600 |
| 2026-05-12 | $76.94 | 18,430,100 |
| 2026-05-11 | $76.67 | 15,641,100 |
| 2026-05-08 | $82.83 | 17,187,000 |
| 2026-05-07 | $87.31 | 29,922,900 |
| 2026-05-06 | $111.22 | 5,274,400 |
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
đ° Latest News
2 Cash-Producing Stocks Worth Your Attention and 1 Facing Headwinds
StockStory âĸ 2026-06-05T15:04:14ZJim Cramer Recommends Elanco Over Zoetis
Insider Monkey âĸ 2026-06-05T14:14:36ZA Look At Zoetis (ZTS) Valuation After Guidance Cut Legal Actions And Companion Animal Headwinds
Simply Wall St. âĸ 2026-06-05T01:08:52ZJim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
Benzinga âĸ 2026-06-04T21:30:37ZStocks Rebound on Strength in Banks and Managed Healthcare
Barchart âĸ 2026-06-04T20:32:37ZA Flesh-Eating Fly Adds to the Beef Industryâs List of Problems
Barrons.com âĸ 2026-06-04T20:21:00ZStocks Mixed as Tech Weakness Weighs
Barchart âĸ 2026-06-04T15:16:14Z3 Large-Cap Stocks with Solid Fundamentals
StockStory âĸ 2026-06-03T13:03:33ZHow Is Zoetisâ Stock Performance Compared to Other Healthcare Stocks?
Barchart âĸ 2026-06-03T12:34:03ZWhy Zoetis Inc. (ZTS) Was Downgraded Following Steep Market Selloff?
Insider Monkey âĸ 2026-06-02T14:11:02ZIncome Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $2,307,000,000 | $2,363,000,000 | $2,219,000,000 | $2,139,000,000 |
| Cost Of Revenue | $2,666,000,000 | $2,719,000,000 | $2,561,000,000 | $2,454,000,000 |
| Total Revenue | $9,467,000,000 | $9,256,000,000 | $8,544,000,000 | $8,080,000,000 |
| Operating Revenue | $9,467,000,000 | $9,256,000,000 | $8,544,000,000 | $8,080,000,000 |
| Expenses | ||||
| Interest Expense | $222,000,000 | $225,000,000 | $239,000,000 | $221,000,000 |
| Total Expenses | $5,870,000,000 | $5,864,000,000 | $5,475,000,000 | $5,152,000,000 |
| Other Income Expense | $-108,000,000 | $-140,000,000 | $1,000,000 | $-101,000,000 |
| Other Non Operating Income Expenses | $-4,000,000 | $1,000,000 | $35,000,000 | $18,000,000 |
| Net Non Operating Interest Income Expense | $-129,000,000 | $-119,000,000 | $-134,000,000 | $-171,000,000 |
| Interest Expense Non Operating | $222,000,000 | $225,000,000 | $239,000,000 | $221,000,000 |
| Operating Expense | $3,204,000,000 | $3,145,000,000 | $2,914,000,000 | $2,698,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $2,673,000,000 | $2,486,000,000 | $2,344,000,000 | $2,114,000,000 |
| Net Interest Income | $-129,000,000 | $-119,000,000 | $-134,000,000 | $-171,000,000 |
| Interest Income | $93,000,000 | $106,000,000 | $105,000,000 | $50,000,000 |
| Normalized Income | $2,755,784,000 | $2,598,377,000 | $2,371,098,000 | $2,208,581,702 |
| Net Income From Continuing And Discontinued Operation | $2,673,000,000 | $2,486,000,000 | $2,344,000,000 | $2,114,000,000 |
| Net Income Common Stockholders | $2,673,000,000 | $2,486,000,000 | $2,344,000,000 | $2,114,000,000 |
| Net Income | $2,673,000,000 | $2,486,000,000 | $2,344,000,000 | $2,114,000,000 |
| Net Income Including Noncontrolling Interests | $2,673,000,000 | $2,496,000,000 | $2,340,000,000 | $2,111,000,000 |
| Net Income Continuous Operations | $2,673,000,000 | $2,496,000,000 | $2,340,000,000 | $2,111,000,000 |
| Pretax Income | $3,360,000,000 | $3,133,000,000 | $2,936,000,000 | $2,656,000,000 |
| Special Income Charges | $-59,000,000 | $-91,000,000 | $13,000,000 | $-57,000,000 |
| Interest Income Non Operating | $93,000,000 | $106,000,000 | $105,000,000 | $50,000,000 |
| Operating Income | $3,597,000,000 | $3,392,000,000 | $3,069,000,000 | $2,928,000,000 |
| Depreciation Amortization Depletion Income Statement | $128,000,000 | $141,000,000 | $149,000,000 | $150,000,000 |
| Depreciation And Amortization In Income Statement | $128,000,000 | $141,000,000 | $149,000,000 | $150,000,000 |
| Amortization Of Intangibles Income Statement | $128,000,000 | $141,000,000 | $149,000,000 | $150,000,000 |
| Gross Profit | $6,801,000,000 | $6,537,000,000 | $5,983,000,000 | $5,626,000,000 |
| Per Share | ||||
| Diluted EPS | $6.02 | $5.47 | $5.07 | $4.49 |
| Basic EPS | $6.03 | $5.47 | $5.08 | $4.51 |
| Other | ||||
| Tax Effect Of Unusual Items | $-21,216,000 | $-28,623,000 | $-6,902,000 | $-24,418,298 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $4,173,000,000 | $3,996,000,000 | $3,700,000,000 | $3,461,000,000 |
| Total Unusual Items | $-104,000,000 | $-141,000,000 | $-34,000,000 | $-119,000,000 |
| Total Unusual Items Excluding Goodwill | $-104,000,000 | $-141,000,000 | $-34,000,000 | $-119,000,000 |
| Reconciled Depreciation | $487,000,000 | $497,000,000 | $491,000,000 | $465,000,000 |
| EBITDA (Bullshit earnings) | $4,069,000,000 | $3,855,000,000 | $3,666,000,000 | $3,342,000,000 |
| EBIT | $3,582,000,000 | $3,358,000,000 | $3,175,000,000 | $2,877,000,000 |
| Diluted Average Shares | $443,835,000 | $454,800,000 | $462,300,000 | $470,400,000 |
| Basic Average Shares | $443,443,000 | $454,200,000 | $461,200,000 | $468,900,000 |
| Diluted NI Availto Com Stockholders | $2,673,000,000 | $2,486,000,000 | $2,344,000,000 | $2,114,000,000 |
| Minority Interests | $0 | $-10,000,000 | $4,000,000 | $3,000,000 |
| Tax Provision | $687,000,000 | $637,000,000 | $596,000,000 | $545,000,000 |
| Gain On Sale Of Ppe | $0 | $-16,000,000 | $0 | $0 |
| Gain On Sale Of Business | $-3,000,000 | $-23,000,000 | $101,000,000 | $0 |
| Write Off | $22,000,000 | $0 | $1,000,000 | $9,000,000 |
| Impairment Of Capital Assets | $5,000,000 | $15,000,000 | $35,000,000 | $39,000,000 |
| Restructuring And Mergern Acquisition | $29,000,000 | $37,000,000 | $52,000,000 | $9,000,000 |
| Gain On Sale Of Security | $-45,000,000 | $-50,000,000 | $-47,000,000 | $-62,000,000 |
| Amortization | $128,000,000 | $141,000,000 | $149,000,000 | $150,000,000 |
| Research And Development | $698,000,000 | $686,000,000 | $614,000,000 | $539,000,000 |
| Selling General And Administration | $2,378,000,000 | $2,318,000,000 | $2,151,000,000 | $2,009,000,000 |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-434,000,000 | $919,000,000 | $900,000,000 | $279,000,000 |
| Total Assets | $15,467,000,000 | $14,237,000,000 | $14,286,000,000 | $14,925,000,000 |
| Total Non Current Assets | $8,699,000,000 | $8,251,000,000 | $7,943,000,000 | $7,419,000,000 |
| Other Non Current Assets | $328,000,000 | $250,000,000 | $206,000,000 | $147,000,000 |
| Non Current Deferred Assets | $637,000,000 | $540,000,000 | $206,000,000 | $173,000,000 |
| Non Current Deferred Taxes Assets | $637,000,000 | $540,000,000 | $206,000,000 | $173,000,000 |
| Goodwill And Other Intangible Assets | $3,765,000,000 | $3,851,000,000 | $4,097,000,000 | $4,126,000,000 |
| Other Intangible Assets | $998,000,000 | $1,127,000,000 | $1,338,000,000 | $1,380,000,000 |
| Current Assets | $6,768,000,000 | $5,986,000,000 | $6,343,000,000 | $7,506,000,000 |
| Other Current Assets | $436,000,000 | $377,000,000 | $434,000,000 | $365,000,000 |
| Restricted Cash | $2,000,000 | $2,000,000 | $2,000,000 | $4,000,000 |
| Inventory | $2,430,000,000 | $2,306,000,000 | $2,564,000,000 | $2,345,000,000 |
| Receivables | $1,590,000,000 | $1,316,000,000 | $1,304,000,000 | $1,215,000,000 |
| Accounts Receivable | $1,590,000,000 | $1,316,000,000 | $1,304,000,000 | $1,215,000,000 |
| Allowance For Doubtful Accounts Receivable | $-16,000,000 | $-18,000,000 | $-18,000,000 | $-19,000,000 |
| Gross Accounts Receivable | $1,606,000,000 | $1,334,000,000 | $1,322,000,000 | $1,234,000,000 |
| Cash Cash Equivalents And Short Term Investments | $2,310,000,000 | $1,985,000,000 | $2,039,000,000 | $3,577,000,000 |
| Cash And Cash Equivalents | $2,310,000,000 | $1,985,000,000 | $2,039,000,000 | $3,577,000,000 |
| Debt | ||||
| Net Debt | $6,732,000,000 | $4,585,000,000 | $4,528,000,000 | $4,327,000,000 |
| Total Debt | $9,238,000,000 | $6,744,000,000 | $6,755,000,000 | $8,090,000,000 |
| Long Term Debt And Capital Lease Obligation | $9,238,000,000 | $5,394,000,000 | $6,752,000,000 | $6,738,000,000 |
| Long Term Debt | $9,042,000,000 | $5,220,000,000 | $6,564,000,000 | $6,552,000,000 |
| Current Debt And Capital Lease Obligation | - | $1,350,000,000 | $3,000,000 | $1,352,000,000 |
| Current Debt | - | $1,350,000,000 | $3,000,000 | $1,352,000,000 |
| Other Current Borrowings | - | $1,350,000,000 | - | $1,350,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $12,136,000,000 | $9,467,000,000 | $9,295,000,000 | $10,522,000,000 |
| Total Non Current Liabilities Net Minority Interest | $9,901,000,000 | $6,055,000,000 | $7,406,000,000 | $7,355,000,000 |
| Other Non Current Liabilities | $248,000,000 | $222,000,000 | $237,000,000 | $217,000,000 |
| Tradeand Other Payables Non Current | $276,000,000 | $272,000,000 | $271,000,000 | $258,000,000 |
| Non Current Deferred Liabilities | $139,000,000 | $167,000,000 | $146,000,000 | $142,000,000 |
| Non Current Deferred Taxes Liabilities | $139,000,000 | $167,000,000 | $146,000,000 | $142,000,000 |
| Current Liabilities | $2,235,000,000 | $3,412,000,000 | $1,889,000,000 | $3,167,000,000 |
| Other Current Liabilities | $107,000,000 | $125,000,000 | $102,000,000 | $97,000,000 |
| Payables And Accrued Expenses | $1,718,000,000 | $1,496,000,000 | $1,402,000,000 | $1,418,000,000 |
| Payables | $866,000,000 | $750,000,000 | $719,000,000 | $736,000,000 |
| Dividends Payable | $232,000,000 | $224,000,000 | $198,000,000 | $174,000,000 |
| Total Tax Payable | $147,000,000 | $93,000,000 | $110,000,000 | $157,000,000 |
| Income Tax Payable | $147,000,000 | $93,000,000 | $110,000,000 | $157,000,000 |
| Accounts Payable | $487,000,000 | $433,000,000 | $411,000,000 | $405,000,000 |
| Equity | ||||
| Common Stock Equity | $3,331,000,000 | $4,770,000,000 | $4,997,000,000 | $4,405,000,000 |
| Total Equity Gross Minority Interest | $3,331,000,000 | $4,770,000,000 | $4,991,000,000 | $4,403,000,000 |
| Stockholders Equity | $3,331,000,000 | $4,770,000,000 | $4,997,000,000 | $4,405,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-834,000,000 | $-940,000,000 | $-839,000,000 | $-817,000,000 |
| Other Equity Adjustments | $-834,000,000 | $-940,000,000 | $-839,000,000 | $-817,000,000 |
| Retained Earnings | $13,744,000,000 | $11,968,000,000 | $10,295,000,000 | $8,668,000,000 |
| Other | ||||
| Treasury Shares Number | $76,963,708 | $53,418,170 | $43,523,885 | $38,083,184 |
| Ordinary Shares Number | $424,927,535 | $448,473,073 | $458,367,358 | $463,808,059 |
| Share Issued | $501,891,243 | $501,891,243 | $501,891,243 | $501,891,243 |
| Tangible Book Value | $-434,000,000 | $919,000,000 | $900,000,000 | $279,000,000 |
| Invested Capital | $12,373,000,000 | $11,340,000,000 | $11,564,000,000 | $12,309,000,000 |
| Working Capital | $4,533,000,000 | $2,574,000,000 | $4,454,000,000 | $4,339,000,000 |
| Capital Lease Obligations | $196,000,000 | $174,000,000 | $188,000,000 | $186,000,000 |
| Total Capitalization | $12,373,000,000 | $9,990,000,000 | $11,561,000,000 | $10,957,000,000 |
| Minority Interest | $0 | $0 | $-6,000,000 | $-2,000,000 |
| Treasury Stock | $10,685,000,000 | $7,445,000,000 | $5,597,000,000 | $4,539,000,000 |
| Additional Paid In Capital | $1,101,000,000 | $1,182,000,000 | $1,133,000,000 | $1,088,000,000 |
| Capital Stock | $5,000,000 | $5,000,000 | $5,000,000 | $5,000,000 |
| Common Stock | $5,000,000 | $5,000,000 | $5,000,000 | $5,000,000 |
| Long Term Capital Lease Obligation | $196,000,000 | $174,000,000 | $188,000,000 | $186,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $410,000,000 | $441,000,000 | $382,000,000 | $300,000,000 |
| Current Accrued Expenses | $852,000,000 | $746,000,000 | $683,000,000 | $682,000,000 |
| Goodwill | $2,767,000,000 | $2,724,000,000 | $2,759,000,000 | $2,746,000,000 |
| Net PPE | $3,969,000,000 | $3,610,000,000 | $3,434,000,000 | $2,973,000,000 |
| Accumulated Depreciation | $-2,925,000,000 | $-2,635,000,000 | $-2,594,000,000 | $-2,297,000,000 |
| Gross PPE | $6,894,000,000 | $6,245,000,000 | $6,028,000,000 | $5,270,000,000 |
| Construction In Progress | $1,295,000,000 | $1,353,000,000 | $1,085,000,000 | $814,000,000 |
| Other Properties | $288,000,000 | $219,000,000 | $230,000,000 | $220,000,000 |
| Machinery Furniture Equipment | $3,729,000,000 | $3,353,000,000 | $3,372,000,000 | $3,013,000,000 |
| Buildings And Improvements | $1,549,000,000 | $1,292,000,000 | $1,316,000,000 | $1,197,000,000 |
| Land And Improvements | $33,000,000 | $28,000,000 | $25,000,000 | $26,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,106,000,000 | $996,000,000 | $1,147,000,000 | $1,090,000,000 |
| Work In Process | $962,000,000 | $933,000,000 | $966,000,000 | $825,000,000 |
| Raw Materials | $362,000,000 | $377,000,000 | $451,000,000 | $430,000,000 |
| Line Of Credit | - | $0 | $3,000,000 | $2,000,000 |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $2,283,000,000 | $2,298,000,000 | $1,621,000,000 | $1,326,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $2,904,000,000 | $2,953,000,000 | $2,353,000,000 | $1,912,000,000 |
| Cash Flow From Continuing Operating Activities | $2,904,000,000 | $2,953,000,000 | $2,353,000,000 | $1,912,000,000 |
| Operating Gains Losses | $14,000,000 | $23,000,000 | $-118,000,000 | $117,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-621,000,000 | $-655,000,000 | $-732,000,000 | $-586,000,000 |
| Investing Cash Flow | $-748,000,000 | $-315,000,000 | $-777,000,000 | $-883,000,000 |
| Cash Flow From Continuing Investing Activities | $-748,000,000 | $-315,000,000 | $-777,000,000 | $-883,000,000 |
| Net Other Investing Changes | $1,000,000 | $-2,000,000 | $6,000,000 | $1,000,000 |
| Capital Expenditure Reported | $-621,000,000 | $-655,000,000 | $-732,000,000 | $-586,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-3,235,000,000 | $-1,858,000,000 | $-1,092,000,000 | $-1,594,000,000 |
| Financing Cash Flow | $-1,870,000,000 | $-2,660,000,000 | $-3,109,000,000 | $-904,000,000 |
| Cash Flow From Continuing Financing Activities | $-1,870,000,000 | $-2,660,000,000 | $-3,109,000,000 | $-904,000,000 |
| Net Other Financing Charges | $-233,000,000 | $-5,000,000 | $-3,000,000 | $-11,000,000 |
| Cash Dividends Paid | $-889,000,000 | $-786,000,000 | $-692,000,000 | $-611,000,000 |
| Common Stock Dividend Paid | $-889,000,000 | $-786,000,000 | $-692,000,000 | $-611,000,000 |
| Net Common Stock Issuance | $-3,235,000,000 | $-1,858,000,000 | $-1,092,000,000 | $-1,594,000,000 |
| Other | ||||
| Repayment Of Debt | $-1,350,000,000 | $0 | $-1,350,000,000 | $0 |
| Issuance Of Debt | $3,848,000,000 | $0 | $0 | $1,348,000,000 |
| Interest Paid Supplemental Data | $261,000,000 | $274,000,000 | $295,000,000 | $242,000,000 |
| Income Tax Paid Supplemental Data | $715,000,000 | $892,000,000 | $754,000,000 | $638,000,000 |
| End Cash Position | $2,312,000,000 | $1,987,000,000 | $2,041,000,000 | $3,581,000,000 |
| Beginning Cash Position | $1,987,000,000 | $2,041,000,000 | $3,581,000,000 | $3,485,000,000 |
| Effect Of Exchange Rate Changes | $39,000,000 | $-32,000,000 | $-7,000,000 | $-29,000,000 |
| Changes In Cash | $286,000,000 | $-22,000,000 | $-1,533,000,000 | $125,000,000 |
| Proceeds From Stock Option Exercised | $-11,000,000 | $-8,000,000 | $27,000,000 | $-38,000,000 |
| Common Stock Payments | $-3,235,000,000 | $-1,858,000,000 | $-1,092,000,000 | $-1,594,000,000 |
| Net Issuance Payments Of Debt | $2,498,000,000 | $-3,000,000 | $-1,349,000,000 | $1,350,000,000 |
| Net Short Term Debt Issuance | $0 | $-3,000,000 | $1,000,000 | $2,000,000 |
| Net Long Term Debt Issuance | $2,498,000,000 | $0 | $-1,350,000,000 | $1,348,000,000 |
| Long Term Debt Payments | $-1,350,000,000 | $0 | $-1,350,000,000 | $0 |
| Long Term Debt Issuance | $3,848,000,000 | $0 | $0 | $1,348,000,000 |
| Net Investment Purchase And Sale | $-100,000,000 | $57,000,000 | $8,000,000 | $14,000,000 |
| Purchase Of Investment | $-100,000,000 | $-5,000,000 | $-4,000,000 | $-9,000,000 |
| Net Business Purchase And Sale | $-28,000,000 | $285,000,000 | $-59,000,000 | $-312,000,000 |
| Purchase Of Business | $-28,000,000 | $-8,000,000 | $-155,000,000 | $-312,000,000 |
| Change In Working Capital | $-408,000,000 | $79,000,000 | $-512,000,000 | $-699,000,000 |
| Change In Other Working Capital | $61,000,000 | $-17,000,000 | $-34,000,000 | $98,000,000 |
| Change In Other Current Liabilities | $85,000,000 | $114,000,000 | $67,000,000 | $-180,000,000 |
| Change In Other Current Assets | $-165,000,000 | $52,000,000 | $-95,000,000 | $35,000,000 |
| Change In Payables And Accrued Expense | $46,000,000 | $31,000,000 | $13,000,000 | $-29,000,000 |
| Change In Payable | $46,000,000 | $31,000,000 | $13,000,000 | $-29,000,000 |
| Change In Account Payable | $46,000,000 | $31,000,000 | $13,000,000 | $-29,000,000 |
| Change In Inventory | $-199,000,000 | $-40,000,000 | $-361,000,000 | $-486,000,000 |
| Change In Receivables | $-236,000,000 | $-61,000,000 | $-102,000,000 | $-137,000,000 |
| Changes In Account Receivables | $-236,000,000 | $-61,000,000 | $-102,000,000 | $-137,000,000 |
| Other Non Cash Items | $-8,000,000 | $-6,000,000 | $-8,000,000 | $13,000,000 |
| Stock Based Compensation | $83,000,000 | $74,000,000 | $60,000,000 | $62,000,000 |
| Provisionand Write Offof Assets | $68,000,000 | $97,000,000 | $115,000,000 | $76,000,000 |
| Asset Impairment Charge | $47,000,000 | $31,000,000 | $46,000,000 | $53,000,000 |
| Deferred Tax | $-52,000,000 | $-338,000,000 | $-61,000,000 | $-286,000,000 |
| Deferred Income Tax | $-52,000,000 | $-338,000,000 | $-61,000,000 | $-286,000,000 |
| Depreciation Amortization Depletion | $487,000,000 | $497,000,000 | $491,000,000 | $465,000,000 |
| Depreciation And Amortization | $487,000,000 | $497,000,000 | $491,000,000 | $465,000,000 |
| Amortization Cash Flow | $157,000,000 | - | - | - |
| Amortization Of Intangibles | $157,000,000 | - | - | - |
| Depreciation | $330,000,000 | - | - | - |
| Gain Loss On Investment Securities | $11,000,000 | - | - | $114,000,000 |
| Gain Loss On Sale Of Business | $3,000,000 | $23,000,000 | $-118,000,000 | $0 |
| Net Income From Continuing Operations | $2,673,000,000 | $2,496,000,000 | $2,340,000,000 | $2,111,000,000 |
| Sale Of Investment | - | $62,000,000 | $12,000,000 | $23,000,000 |
| Sale Of Business | - | $293,000,000 | $96,000,000 | $0 |
| Pension And Employee Benefit Expense | - | $0 | $0 | $3,000,000 |